TABLE 2.
Aztreonam-avibactam and comparator agents tested against clinical isolates of S. maltophilia collected worldwide and stratified by geographic region (2016–2019)
| Region or characteristica (no. of isolates) | % of isolates susceptibleb to: |
||||||
|---|---|---|---|---|---|---|---|
| ATM-AVI | TMP-SMX | Minocycline | Levofloxacin | Ceftazidime | Tigecycline | Colistin | |
| All (1,839) | 97.8 | 95.4 | 99.5 | 78.0 | 20.9 | 85.0 | 41.4 |
| W-EU (388) | 96.6 | 96.9 | 100.0 | 84.3 | 17.3 | 88.9 | 42.8 |
| E-EU (156) | 98.7 | 93.5 | 100.0 | 78.8 | 16.7 | 84.0 | 42.9 |
| NA (1,095) | 98.1 | 95.0 | 99.2 | 74.0 | 22.0 | 83.0 | 41.6 |
| LATAM (92) | 100.0 | 96.7 | 100.0 | 88.0 | 30.4 | 88.0 | 29.3 |
| APAC (108) | 96.3 | 95.3 | 99.0 | 87.0 | 21.3 | 90.7 | 42.6 |
| TMP-SMX-NS (85) | 84.7 | 0.0 | 92.4 | 30.6 | 14.1 | 66.7 | 40.0 |
W-EU, Western Europe; E-EU, Eastern Europe; NA, North America; LATAM, Latin America; APAC, Asia-Pacific region; TMP-SMX-NS, isolates not susceptible to trimethoprim-sulfamethoxazole (17).
For TMP-SMX, minocycline, levofloxacin, and ceftazidime, the percentage of isolates susceptible by CLSI criteria is shown. For aztreonam-avibactam (ATM-AVI), the percentage inhibited at ≤8 mg/liter is shown for purposes of comparison (18). For tigecycline, the percentage inhibited at ≤2 mg/liter, the U.S. FDA susceptible breakpoint for Enterobacterales, is shown (21). For colistin, the percentage inhibited at ≤2 mg/liter, the CLSI susceptible breakpoint for P. aeruginosa, is shown (17) for comparison.